---
figid: PMC9357610__JCMM-26-4548-g003
pmcid: PMC9357610
image_filename: JCMM-26-4548-g003.jpg
figure_link: /pmc/articles/PMC9357610/figure/jcmm17478-fig-0003/
number: FIGURE 3
figure_title: ''
caption: 'Pirfenidone alleviated cardiac fibroblasts (CFs) proliferation and transformation
  stimulated by AngII in vitro. (A) Relative inhibitory rate of CFs in different concentrations
  of PFD (n = 6–8). (B) Relative cell viability of CFs at the administration of PFD
  and AngII (n = 6–8). (C–E) Representative immunofluorescent staining photographs
  and relative fluorescent intensity of Vimentin and α–SMA in the Ctrl, PFD, AngII,
  AngII + PFD groups in vitro (n = 3). Scale bar = 10 μm. (F, G) Western blotting
  and relative expression of α‐SMA in CFs in vitro(n = 4–6). (H, I) Western blotting
  and relative expression of Vimentin in CFs in vitro (n = 4–5). *p < 0.05, **p < 0.01
  vs. Ctrl group; #p < 0.05, ##p < 0.01 vs. AngII group'
article_title: Pirfenidone alleviates cardiac fibrosis induced by pressure overload
  via inhibiting TGF‐β1/Smad3 signalling pathway.
citation: Na Li, et al. J Cell Mol Med. 2022 Aug;26(16):4548-4555.
year: '2022'

doi: 10.1111/jcmm.17478
journal_title: Journal of Cellular and Molecular Medicine
journal_nlm_ta: J Cell Mol Med
publisher_name: John Wiley and Sons Inc.

keywords:
- cardiac fibrosis
- cardiac remodelling
- pirfenidone
- pressure overload
- transforming growth factor‐β1

---
